SS18::SSX and BRD9 Modulate Synovial Sarcoma Differentiation
Cells · 2025
DOI: 10.3390/cells14242022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Anna Kuntze und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany. Hauptthemen laut MEDLINE: Sarcoma, Synovial, Cell Differentiation, Transcription Factors, DNA-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Synovial sarcoma (SySa) is a malignant soft tissue tumor that is characterized by an SS18::SSX fusion protein, which integrates into BAF chromatin remodeling complexes and alters global gene transcription. Despite its uniform genetic driver, SySa displays striking histomorphological and phenotypic heterogeneity, including spindle cell, glandular and poorly differentiated patterns. Prognosis is variable, with around 50% of patients developing metastases. Limited response to chemotherapy highlights the need for a better understanding of the underlying molecular mechanisms to guide alternative therapeutic strategies. Given the pivotal function of BAF complexes in SySa and their recently described impact on cellular differentiation processes, this study aims to investigate the role of SS18::SSX and specific BAF subunits in SySa differentiation. Nanostring analysis revealed that silencing of SS18::SSX and the GBAF subunit BRD9 modulates the cellular differentiation pathways. SS18::SSX and BRD9 were found to regulate epithelial–mesenchymal-transition (EMT)-associated factors of Snail and Slug on different levels, with SS18::SSX repressing E-Cadherin expression. Published single-cell RNA sequencing data were analyzed to validate our finding that BRD9 contributes to SySa EMT regulation. Our study provides novel insights into the multilayered regulation of key EMT players by SS18::SSX and BRD9 in SySa, thereby defining tumor phenotype and (potentially) prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany.
- Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, 48149 Münster, Germany.
ORCID-Profile: Anna Kuntze, Marcel Trautmann, Ruth Berthold, Pascal Hauser, Eva Wardelmann, Ilka Isfort
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Kuntze, A., Banerjee, V., Trautmann, M., Pünt, C., Berthold, R., Hauser, P., Scholl, L., Wardelmann, E., Kerl, K., Hartmann, W., & Isfort, I. (2025). SS18::SSX and BRD9 Modulate Synovial Sarcoma Differentiation. Cells. https://doi.org/10.3390/cells14242022
Vancouver
Kuntze A, Banerjee V, Trautmann M, Pünt C, Berthold R, Hauser P, et al. SS18::SSX and BRD9 Modulate Synovial Sarcoma Differentiation. Cells. 2025. doi:10.3390/cells14242022
BibTeX
@article{Kuntze2025,
author = {Kuntze, Anna and Banerjee, Victor and Trautmann, Marcel and Pünt, Charlotte and Berthold, Ruth and Hauser, Pascal and Scholl, Lucas and Wardelmann, Eva and Kerl, Kornelius and Hartmann, Wolfgang and Isfort, Ilka},
title = {SS18::SSX and BRD9 Modulate Synovial Sarcoma Differentiation},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14242022}
}
EUVIMED